Serving leading biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving leading biopharmaceutical companies globally:
Generated: October 19, 2017
What is the competitive landscape for TAKEDA, and what generic alternatives to TAKEDA drugs are available?
TAKEDA has twenty-one approved drugs.| International Patents: | 1068 |
| US Patents: | 83 |
| Tradenames: | 22 |
| Ingredients: | 16 |
| NDAs: | 21 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
alogliptin and metformin hydrochloride | Tablets | 12.5 mg/500 mg and 12.5 mg/1000 mg | KAZANO | 1/25/2017 |
alogliptin | Tablets | 6.25 mg, 12.5 mg and 25 mg | NESINA | 1/25/2017 |
febuxostat | Tablets | 40 mg and 80 mg | ULORIC | 2/13/2013 |
colchicine | Tablets | 0.6 mg | COLCRYS | 12/23/2011 |
pioglitazone hydrochloride and metformin hydrochloride | Extended-release Tablets | 15 mg/1000 mg and 30 mg/1000 mg | ACTOPLUS MET XR | 9/23/2011 |
dexlansoprazole | Delayed-release Capsule | 30 mg | DEXILANT | 11/30/2010 |
dexlansoprazole | Capsule | 60 mg | DEXILANT | 8/25/2010 |
pioglitazone hydrochloride and glimepiride | Tablets | 30 mg/2 mg and 30 mg/4 mg | DUETACT | 12/22/2009 |
ramelteon | Tablets | 8 mg | ROZEREM | 7/22/2009 |
pioglitazone hydrochloride and metformin hydrochloride | Tablets | 15 mg/500 mg and 15 mg/850 mg | ACTOPLUS MET | 3/6/2008 |
lansoprazole | Delayed-release Orally Disinte | 15 mg and 30 mg | PREVACID | 12/27/2006 |
lansoprazole | Delayed-release Pellets/Capsul | 15 mg and 30 mg | PREVACID | 12/5/2005 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6,251,924 | Pharmaceutical composition | ► Subscribe | |||||||||||||
| 7,569,697 | Benzimidazole compound crystal | ► Subscribe | |||||||||||||
| 6,103,742 | Pharmaceutical composition | ► Subscribe | |||||||||||||
| 9,708,280 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | ► Subscribe | |||||||||||||
| 9,125,910 | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment | ► Subscribe | |||||||||||||
| 6,277,869 | Pharmaceutical composition | ► Subscribe | |||||||||||||
| 7,855,175 | Peptides that bind to the erythropoietin receptor | ► Subscribe | |||||||||||||
| 6,172,089 | Pharmaceutical composition | ► Subscribe | |||||||||||||
| 6,169,099 | Pharmaceutical composition | ► Subscribe | |||||||||||||
| 8,664,225 | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Taiwan | I443091 | ► Subscribe | |||||||||||||
| Taiwan | 200848411 | ► Subscribe | |||||||||||||
| Eurasian Patent Organization | 007537 | ► Subscribe | |||||||||||||
| Argentina | 005641 | ► Subscribe | |||||||||||||
| Ukraine | 93250 | ► Subscribe | |||||||||||||
| South Korea | 100981905 | ► Subscribe | |||||||||||||
| Colombia | 6220962 | ► Subscribe | |||||||||||||
| World Intellectual Property Organization (WIPO) | 9209279 | ► Subscribe | |||||||||||||
| Croatia | P20120989 | ► Subscribe | |||||||||||||
| Slovenia | 1553929 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2010 00015 | Denmark | ► Subscribe | |||||||||||||
| 2008013,C1412357 | Lithuania | ► Subscribe | PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/08/455/001 - EU/1/08/455/014 20080716 | ||||||||||||
| 2010005 | Lithuania | ► Subscribe | PRODUCT NAME: FEBUXOSTATUM; REGISTRATION NO/DATE: EU/1/08/447/001-EU/1/08/447/004 20080421 | ||||||||||||
| C0022 | France | ► Subscribe | PRODUCT NAME: FEBUXOSTAT; REGISTRATION NO/DATE: EU/1/08/447/001-004 20080421 | ||||||||||||
| C 038/2006 | Ireland | ► Subscribe | SPC 038/2006: 20070528, EXPIRES: 20210619 | ||||||||||||
| 00652 | Netherlands | ► Subscribe | PRODUCT NAME: VORTIOXETINE OF EEN; REGISTRATION NO/DATE: EU/1/13/891/001-036 20131218 | ||||||||||||
| 1261586/02 | Switzerland | ► Subscribe | PRODUCT NAME: SAXAGLIPTIN UND METFORMIN; NAT. REGISTRATION NO/DATE: SWISSMEDIC 62040 20120329 | ||||||||||||
| 606 | Luxembourg | ► Subscribe | 91606, EXPIRES: 20210620 | ||||||||||||
| 2013 00001 | Denmark | ► Subscribe | PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3,7-DIHYDROPURIN-2,6-DION ENANTIOMERER OG SALTE DERAF - SAERLIGT LINAGLIPTIN - I KOMBINATION MED METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/12/780/001-028 20120720 | ||||||||||||
| 1084705/05 | Switzerland | ► Subscribe | PRODUCT NAME: ALOGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 62955 21.11.2013 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,948 others who get our Drug Patent Expiration Alerts:
